These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 24035134)

  • 1. Activation of mammalian target of rapamycin signaling pathway markers in minute adenocarcinoma of the prostate.
    Faraj SF; Albadine R; Chaux A; Gonzalez-Roibon N; Hicks J; Humphreys E; Partin A; Netto GJ
    Urology; 2013 Nov; 82(5):1083-9. PubMed ID: 24035134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma.
    Munari E; Fujita K; Faraj S; Chaux A; Gonzalez-Roibon N; Hicks J; Meeker A; Nonomura N; Netto GJ
    Hum Pathol; 2013 Dec; 44(12):2668-76. PubMed ID: 24074531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High levels of phosphatase and tensin homolog expression are associated with tumor progression, tumor recurrence, and systemic metastases in pT1 urothelial carcinoma of the bladder: a tissue microarray study of 156 patients treated by transurethral resection.
    Chaux A; Compérat E; Varinot J; Hicks J; Lecksell K; Solus J; Netto GJ
    Urology; 2013 Jan; 81(1):116-22. PubMed ID: 23273076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of mTOR signaling pathway markers in prostate cancer progression.
    Kremer CL; Klein RR; Mendelson J; Browne W; Samadzedeh LK; Vanpatten K; Highstrom L; Pestano GA; Nagle RB
    Prostate; 2006 Aug; 66(11):1203-12. PubMed ID: 16652388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics.
    Dai B; Kong YY; Ye DW; Ma CG; Zhou X; Yao XD
    BJU Int; 2009 Oct; 104(7):1009-16. PubMed ID: 19389013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of PI3K/Akt/mTOR signaling pathway triggered by PTEN downregulation in the pathogenesis of Crohn's disease.
    Long SH; He Y; Chen MH; Cao K; Chen YJ; Chen BL; Mao R; Zhang SH; Zhu ZH; Zeng ZR; Hu PJ
    J Dig Dis; 2013 Dec; 14(12):662-9. PubMed ID: 23962154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.
    Nishikawa M; Miyake H; Harada K; Fujisawa M
    Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of mTOR Pathway Markers and Clinical Outcomes in Patients with Intermediate-/High-risk Prostate Cancer: Long-Term Analysis.
    Barata PC; Magi-Galluzzi C; Gupta R; Dreicer R; Klein EA; Garcia JA
    Clin Genitourin Cancer; 2019 Oct; 17(5):366-372. PubMed ID: 31262501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical characterization of the mTOR pathway in stage-I non-small-cell lung carcinoma.
    Shin E; Choi CM; Kim HR; Jang SJ; Park YS
    Lung Cancer; 2015 Jul; 89(1):13-8. PubMed ID: 25936472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the mammalian target of rapamycin pathway markers in lung adenocarcinoma and squamous cell carcinoma.
    Kim HS; Kim GY; Lim SJ; Kim YW
    Pathobiology; 2012; 79(2):84-93. PubMed ID: 22286903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder.
    Nishikawa M; Miyake H; Behnsawy HM; Fujisawa M
    Urol Oncol; 2015 Apr; 33(4):166.e9-15. PubMed ID: 25618298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell carcinomas.
    Chaux A; Albadine R; Schultz L; Hicks J; Carducci MA; Argani P; Allaf M; Netto GJ
    Hum Pathol; 2013 Oct; 44(10):2323-30. PubMed ID: 23953228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammalian target of rapamycin signaling activation patterns in pancreatic neuroendocrine tumors.
    Komori Y; Yada K; Ohta M; Uchida H; Iwashita Y; Fukuzawa K; Kashima K; Yokoyama S; Inomata M; Kitano S
    J Hepatobiliary Pancreat Sci; 2014 Apr; 21(4):288-95. PubMed ID: 24002888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy.
    Schultz L; Albadine R; Hicks J; Jadallah S; DeMarzo AM; Chen YB; Nielsen ME; Gonzalgo ML; Sidransky D; Schoenberg M; Netto GJ
    Cancer; 2010 Dec; 116(23):5517-26. PubMed ID: 20939013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas.
    Setsu N; Yamamoto H; Kohashi K; Endo M; Matsuda S; Yokoyama R; Nishiyama K; Iwamoto Y; Dobashi Y; Oda Y
    Cancer; 2012 Mar; 118(6):1637-48. PubMed ID: 21837670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mammalian target of rapamycin signaling pathway contributes to glioma progression and patients' prognosis.
    Yang J; Liao D; Wang Z; Liu F; Wu G
    J Surg Res; 2011 Jun; 168(1):97-102. PubMed ID: 20036387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral Heterogeneity Determines the Expression of mTOR-pathway Proteins in Prostate Cancer.
    Russo GI; Hennenlotter J; Vogel U; Kühs U; Wurm TM; Gerber V; Neumann T; Cimino S; Stenzl A; Todenhöfer T
    Dis Markers; 2019; 2019():1296865. PubMed ID: 31885728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mTOR pathway is frequently activated in pancreatic ductal adenocarcinoma and chronic pancreatitis.
    Bellizzi AM; Bloomston M; Zhou XP; Iwenofu OH; Frankel WL
    Appl Immunohistochem Mol Morphol; 2010 Oct; 18(5):442-7. PubMed ID: 20661135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas.
    Schultz L; Chaux A; Albadine R; Hicks J; Kim JJ; De Marzo AM; Allaf ME; Carducci MA; Rodriguez R; Hammers HJ; Argani P; Reuter VE; Netto GJ
    Am J Surg Pathol; 2011 Oct; 35(10):1549-56. PubMed ID: 21881486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.